Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 08, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO PIONEERING BETTER, GENTLER MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED SEVERAL STRATEGIC APPOINTMENTS STRENGTHENING ITS EXECUTIVE LEADERSHIP TEAM TO SUPPORT THE COMPANY'S NEXT PHASE OF DEVELOPMENT.

OVID THERAPEUTICS STRENGTHENS EXECUTIVE LEADERSHIP TEAM TO SUPPORT CONTINUED PIPELINE PROGRESS AND NEXT PHASE OF DEVELOPMENT

NEW YORK, JUNE 04, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO PIONEERING BETTER, GENTLER MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES:

OVID THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

NEW YORK, JUNE 03, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO PIONEERING BETTER, GENTLER MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THE APPOINTMENT OF ANNA GREKA, M.D., PH.D., TO ITS BOARD OF DIRECTORS, EFFECTIVE JUNE 15, 2026.

OVID THERAPEUTICS APPOINTS LEADING PHYSICIAN-SCIENTIST AND BIOTECH INNOVATOR ANNA GREKA, M.D., PH.D., TO BOARD OF DIRECTORS

DOSED FIRST PARTICIPANT WITH OV4071, THE FIRST-EVER ORAL POTASSIUM-CHLORIDE COTRANSPORTER 2 (KCC2) DIRECT ACTIVATOR, IN MAY 2026 IN A PHASE 1 STUDY WITH HEALTHY VOLUNTEERS OV329 SHOWED FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND DRUG EXPOSURE AT HIGHER DOSES, SUPPORTING THE PLANNED ADVANCEMENT OF PHASE 2 AND PROOF-OF-CONCEPT STUDIES ANNOUNCED DEVELOPMENT EXPANSION OF OV329 INTO ADDITIONAL PEDIATRIC INDICATIONS OF TUBEROUS SCLEROSIS COMPLEX (TSC) SEIZURES AND INFANTILE SPASMS (IS), CONDITIONS FOR WHICH GABA-AMINOTRANSFERASE (GABA-AT) INHIBITION IS A VALIDATED MECHANISM STRENGTHENED BALANCE SHEET, RAISING $60.0 MILLION OF GROSS PROCEEDS IN MARCH 2026 PIPE FINANCING WITH PARTICIPATION FROM LEADING HEALTHCARE INVESTORS RECEIVED $53.9 MILLION IN GROSS PROCEEDS UPON FULL EXERCISE OF SERIES A WARRANTS IN CONNECTION WITH OCTOBER 2025 PIPE FINANCING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $165.6 MILLION AS OF MARCH31, 2026, WHICH DOES NOT INCLUDE $27.3 MILLION IN PROCEEDS RECEIVED IN APRIL 2026 FROM EXERCISE OF SERIES A WARRANTS NEW YORK, MAY 12, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEDICATED TO PIONEERING BETTER, GENTLER MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY PROVIDED BUSINESS UPDATES INCLUDING FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. OUR FIRST QUARTER REFLECTED FOCUSED EXECUTION AND CONTINUED PROGRESS ACROSS OUR PIPELINE OF POTENTIALLY TRANSFORMATIVE SMALL MOLECULE MEDICINES FOR INTRACTABLE BRAIN CONDITIONS, STATED MEG ALEXANDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER.

OVID THERAPEUTICS REPORTS BUSINESS UPDATES AND FIRST QUARTER 2026 FINANCIAL RESULTS

NEW YORK, APRIL 08, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THE COMPANY WILL HOST A KCC2 DEEP DIVE R&D EVENT HIGHLIGHTING ITS FIRST-IN-CLASS KCC2 PORTFOLIO ON TUESDAY, APRIL 14, 2026, AT 9:30 AM ET IN NEW YORK, NY, WHICH WILL ALSO BE WEBCAST SIMULTANEOUSLY. DURING THE EVENT INDEPENDENT EXPERT CLINICIANS AND TRANSLATIONAL EXPERTS AS WELL AS OVID'S PRESIDENT AND CHIEF EXECUTIVE OFFICER MEG ALEXANDER, WILL DISCUSS THE COMPANY'S PROPRIETARY PORTFOLIO OF POTENTIAL FIRST-IN-CLASS DIRECT ACTIVATORS OF KCC2, INCLUDING PHARMACODYNAMIC DATA, TRANSLATIONAL AND CLINICAL DEVELOPMENT STRATEGY, AND THE POTENTIAL MARKET OPPORTUNITY.

OVID THERAPEUTICS TO HOST POTASSIUM-CHLORIDE CO-TRANSPORTER 2 (KCC2) DEEP DIVE R&D EVENT ON TUESDAY, APRIL 14

NEW YORK, MARCH 18, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY PROVIDED PIPELINE PROGRESS AND BUSINESS UPDATES, INCLUDING FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. THE COMPANY REPORTED FAVORABLE TOPLINE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) FINDINGS FROM THE 7 MG DOSE COHORT OF OV329, ITS NEXT GENERATION GABA-AMINOTRANSFERASE (GABA-AT) INHIBITOR. ADDITIONALLY THE COMPANY ANNOUNCED IT WILL ADD COMPLEMENTARY DEVELOPMENT PROGRAMS FOR OV329, EXPANDING INTO TUBEROUS SCLEROSIS COMPLEX (TSC) SEIZURES AND INFANTILE SPASMS (IS) WHICH IS FUNDED BY A PRIVATE PLACEMENT FINANCING EXPECTED TO RESULT IN GROSS PROCEEDS OF $60.0 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OFFERING EXPENSES.

OVIDTHERAPEUTICS ANNOUNCES NEW OV329 DATA AND INDICATION EXPANSION, PHASE 1 CLEARANCE FOR OV4071, AND REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

NEW YORK, MARCH 18, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF $60.0 MILLION TO THE COMPANY, BEFORE PLACEMENT AGENT FEES AND OFFERING EXPENSES. THE PIPE FINANCING IS EXPECTED TO CLOSE ON OR ABOUT MARCH 19, 2026, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

OVID THERAPEUTICS ANNOUNCES PRICING OF $60 MILLION PRIVATE PLACEMENT

NEW YORK, FEB. 25, 2026 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES TO TREAT BRAIN DISORDERS AND SYMPTOMS CAUSED BY EXCESS NEURAL EXCITABILITY, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES: OPPENHEIMER 36TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE  WEDNESDAY, FEBRUARY 25TH AT 11:20 AM ET 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE  WEDNESDAY, MARCH 4TH AT 9:50 AM ET LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE 2026  WEDNESDAY, MARCH 11TH AT 3:00 PM ET A LIVE WEBCAST OF THE PRESENTATIONS CAN BE ACCESSED THROUGH THE EVENTS & PRESENTATIONS SECTION OF THE COMPANY'S WEBSITE AT INVESTORS.OVIDRX.COM. AN ARCHIVED REPLAY OF THE WEBCAST WILL BE AVAILABLE ON THE COMPANY'S WEBSITE FOLLOWING THE LIVE PRESENTATION FOR APPROXIMATELY 30 DAYS.

OV350 SHOWED A GOOD SAFETY PROFILE, SUPPORTING THE ADVANCEMENT OF THE COMPANY'S KCC2 PORTFOLIO, INCLUDING THE FIRST ORAL DIRECT ACTIVATOR, OV4071 THERE WERE NO TREATMENT-RELATED LABORATORY FINDINGS, NO SAFETY FINDINGS, AND NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS (SAES) EXPLORATORY QUANTITATIVE ELECTROPHYSIOLOGY RESULTS SUGGEST OV350 HAD CENTRAL ACTIVITY AND SPECTRAL POWER CONSISTENT WITH EXPECTED PHYSIOLOGICAL EFFECTS OF KCC2 MODULATION; ALIGNED WITH EXPECTED DRUG EXPOSURE IN THE BRAIN PHARMACOKINETICS FOR OV350 WERE AS PREDICTED, AND WILL INFORM DOSING STRATEGIES FOR FUTURE KCC2 DEVELOPMENT PROGRAMS OV4071 (ORAL) IS ON TRACK FOR REGULATORY SUBMISSION FOR A PHASE 1/1B CLINICAL TRIAL IN Q1 2026 NEW YORK, DEC. 18, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES TO TREAT BRAIN DISORDERS AND SYMPTOMS CAUSED BY EXCESS NEURAL EXCITABILITY, TODAY ANNOUNCED RESULTS FROM ITS PHASE 1 STUDY OF OV350, THE FIRST-EVER KCC2 DIRECT ACTIVATOR KNOWN TO BE DOSED IN HUMANS. THE STUDY MET ITS PRIMARY OBJECTIVES TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS.

OVID THERAPEUTICS REPORTS PHASE 1 RESULTS FOR THE FIRST-EVER DIRECT ACTIVATOR OF POTASSIUM-CHLORIDE COTRANSPORTER 2 (KCC2), OV350 INTRAVENOUS (IV)

NEW YORK, DEC. 02, 2025 (GLOBE NEWSWIRE) -- OVID THERAPEUTICS INC. (NASDAQ: OVID), A BIOPHARMACEUTICAL COMPANY DEVELOPING SMALL MOLECULE MEDICINES FOR BRAIN DISORDERS WITH SIGNIFICANT UNMET NEED, TODAY ANNOUNCED THE APPOINTMENT OF PETRA KAUFMANN, M.D., M.S., F.A.A.N., AS CHIEF MEDICAL OFFICER. DR. KAUFMANN JOINS OVID'S LEADERSHIP TEAM WITH RESPONSIBILITY FOR GUIDING CLINICAL, MEDICAL, AND REGULATORY STRATEGY AS THE COMPANY PROGRESSES A CLINICAL PIPELINE OF POTENTIAL BEST- AND FIRST-IN-CLASS THERAPEUTIC CANDIDATES FOR CONDITIONS AND SYMPTOMS DRIVEN BY NEURONAL IMBALANCE.

Ovid Therapeutics Inc.

OVID

Price

Financial Reports

No items found.

Press Releases

Ovid Therapeutics Inc.

OVID.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OVID